Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Safety of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells for Treating Inflammatory Bowel Strictures in Crohn's Disease Patients

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a treatment for Crohn's disease, a condition that causes inflammation in the digestive tract, leading to symptoms like abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. The treatment being tested involves the use of allogeneic adipose tissue-derived mesenchymal stem cells, which are special cells taken from healthy donors' fat tissue. These cells are expanded, meaning they are grown in larger numbers, and then injected into patients to help reduce inflammation and heal the affected areas in the intestines.

The purpose of this study is to evaluate how feasible and safe it is to administer these stem cells through a procedure called laparoscopic administration, which is a minimally invasive surgery. Patients with Crohn's disease who have developed narrowings, or strictures, in their intestines due to inflammation are the focus of this research. The study will observe patients over a period of time to monitor any complications that may arise from the treatment and to see if there are improvements in the condition of the intestinal strictures.

Throughout the study, participants will undergo regular check-ups to assess changes in their symptoms and the condition of their intestines. This will include monitoring the length of the intestinal strictures and evaluating the overall impact on their quality of life. The study aims to provide valuable information on whether this stem cell treatment can be a safe and effective option for managing Crohn's disease-related complications.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the trial

    Upon joining the trial, written consent is required. Eligibility includes being between 18 and 75 years old, having Crohn's disease diagnosed at least 6 months prior, and meeting specific medical criteria.

    Women of childbearing age must have a negative pregnancy test and agree to use effective contraceptive measures during the study.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to confirm the presence of a single inflammatory stenotic lesion in the small bowel or ileocolic area. This lesion should be the cause of intestinal blockage, as demonstrated by specific medical imaging.

  3. Step 3

    Treatment administration

    The treatment involves the laparoscopic administration of allogeneic adipose tissue-derived mesenchymal stem cells (adMSCs). This is done through an injectable solution.

    The procedure aims to evaluate the feasibility and safety of this treatment for inflammatory bowel strictures associated with Crohn's disease.

  4. Step 4

    Monitoring and follow-up

    Regular follow-up visits will be scheduled to monitor the patient's condition and any potential complications from the treatment or anesthesia.

    The change in the length of the stenosis and the patient's condition will be evaluated at 6, 12, 18, 24, 36, and 52 weeks using specific questionnaires and medical imaging.

  5. Step 5

    Completion of the trial

    The trial is expected to conclude by November 30, 2025. The final assessment will include evaluating the overall safety and effectiveness of the treatment.

Who can join the trial?

8 criteria

  • Patients who agree to participate and provide their written consent.
  • Patients aged over 18 years and under 75 years.
  • Patients with Crohn's disease diagnosed at least 6 months earlier, confirmed by clinical tests, endoscopy (a procedure to look inside the digestive tract), tissue samples, and/or imaging tests.
  • Presence of a single inflammatory narrowing (stenotic lesion) in the small bowel or ileocolic area (part of the intestine), or where the small bowel connects to the colon, with a maximum length of 10 cm, shown by a special imaging test called enteroresonance. This narrowing should cause episodes of intestinal blockage or partial blockage. Other inflammatory areas are allowed, but only one should be the clear cause of the blockage.
  • Patients who have been treated with at least one biologic drug and did not respond well to regular doses before increasing the dose or changing/adding another drug. This includes:
    • Anti-TNF drugs (for at least 14 weeks, including starting and maintenance doses): Infliximab, Adalimumab, Certolizumab.
    • Anti-integrin drugs (for at least 14 weeks, including starting and maintenance doses): Vedolizumab.
    • Anti-IL-12/23 drugs (for at least 16 weeks, including starting and maintenance doses): Ustekinumab.
    • Women of childbearing age must have a negative pregnancy test at the start of the study and agree to use effective birth control methods while participating in the study.

Who cannot join the trial?

7 criteria

  • Patients who do not have Crohn's disease cannot participate.
  • Patients with other serious health conditions that might interfere with the study cannot participate.
  • Patients who are pregnant or breastfeeding cannot participate.
  • Patients who have had a recent surgery related to their Crohn's disease cannot participate.
  • Patients who are currently participating in another clinical trial cannot participate.
  • Patients who have a history of severe allergic reactions cannot participate.
  • Patients who are unable to follow the study procedures cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Allogeneic Mesenchymal Stem Cells (adMSC) are special cells that are taken from the fat tissue of healthy donors. These cells have the ability to transform into different types of cells and help repair damaged tissues. In this trial, the stem cells are administered through a minimally invasive surgery called laparoscopy. The goal is to see if these cells can safely and effectively treat narrowings in the intestines caused by Crohn's disease, which is a condition that causes inflammation in the digestive tract.

What is already known about the treatment

Allogeneic Mesenchymal Stem Cells (adMSCs) – This medication is administered laparoscopically, meaning it is delivered directly to the affected area through a minimally invasive surgical procedure. Currently, it is being studied in clinical trials to assess its safety and feasibility for treating inflammatory bowel strictures in patients with Crohn's disease. The main therapeutic indication is to help manage complications associated with Crohn's disease. At the molecular level, these stem cells are believed to help reduce inflammation and promote healing by interacting with the body's immune system. They are classified as a type of regenerative medicine, which aims to repair or replace damaged tissues.

Investigated diseases

Crohn's disease – Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract, primarily affecting the small intestine and colon. It is characterized by periods of active disease, known as flare-ups, and periods of remission. During flare-ups, individuals may experience symptoms such as abdominal pain, diarrhea, fatigue, and weight loss. The inflammation can lead to complications like strictures, which are narrowings of the intestine that can cause blockages. Over time, the disease can cause damage to the intestinal walls, leading to the formation of fistulas or abscesses. The progression of Crohn's disease varies among individuals, with some experiencing mild symptoms and others having more severe manifestations.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-507108-30-00Protocol codeFJD-MEIC-21-01Estimated enrolment20 patientsSponsorInstituto De Investigacion Sanitaria Fundacion Jimenez Diaz

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).